/
About Us

Company Introduction

芳拓生物科技(上海)有限公司

Frontera Therapeutics was founded in September 2019. The company brings together biotech leaders with extensive experience in innovative gene therapy research and development, clinical research, manufacturing, registration and commercialization in both China and the United States.  Frontera is committed to developing and manufacturing high-quality, affordable AAV gene therapy products to meet the unmet needs of patients worldwide suffering from rare and chronic genetic diseases.  

 

Frontera's Founder, and the Chief Executive Officer, Yong Dai, Ph.D.,  is a proven leader in biologics and gene therapy drug development. He has 20 years of industry experience in successfully building organizations, developing strategy, CMC (chemistry, manufacturing, and controls), and the regulatory submissions spanning all stages of drug development.  Before joining Frontera, Dr. Dai most recently served as the Chief Technology Officer at Prevail Therapeutics, a gene therapy company, where he built and led a CMC organization to develop and advance multiple AAV gene therapy drugs for Parkinson’s disease and other neurodegenerative disorders into clinical trials. As part of the founding executive team, he fundamentally helped the company to rapidly achieve its IPO on U.S. NASDAQ stock exchange in 2019 and the acquisition by Eli Lilly in 2020. Prior to Prevail, Dr. Dai worked at uniQure, a gene therapy company, where he served as Head of CMC for the development of all the pipeline programs including a last clinical stage Hemophilia B AAV gene therapy drug, and a commercial stage drug, Glybera®, the world’s first commercial approved AAV gene therapy drug. 

Company Mission: Develop and manufacture high-quality gene therapy products that are affordable to patients worldwide.

Company vision: Aspire to become a leading gene therapy company that patients trust, respected by peer companies, and is recognized by the communities.

Core values:  Innovation, efficiency, integrity, Rigor

Frontera Therapeutics

FOUNDERS

Yong Dai, Ph.D.

Yong Dai, Ph.D.

Yong Dai, Ph.D.

       Yong Dai, Ph.D. is a Founder, and the Chief Executive Officer of Frontera Therapeutics since March 2021. Dr. Dai is a proven leader in biologics and gene therapy drug development. He has 20 years of industry experience in successfully building organizations, developing strategy, CMC (chemistry, manufacturing, and controls), and the regulatory submissions spanning all stages of drug development. Before joining Frontera, Dr. Dai most recently served as the Chief Technology Officer at Prevail Therapeutics, a gene therapy company, where he built and led a CMC organization to develop and advance multiple AAV gene therapy drugs including the Parkinson’s disease and other neurodegenerative disorders to the clinical trials. As part of the founding executive team, he fundamentally helped the company to rapidly achieve its IPO on NASDAQ in 2019 and the acquisition by Eli Lilly in 2020. Prior to Prevail, Dr. Dai worked at uniQure, a gene therapy company, where he led the CMC development of all the pipeline programs including a late clinical stage gene therapy drug for Hemophilia B, and a commercial stage drug, Glybera®, the world’s first commercial approved AAV gene therapy drug. Prior to his time at uniQure, he served as the Head of Process Development Commercial Support at Shire Pharmaceuticals, was responsible for the CMC technical supports of all Shire’s commercial biologics drugs for rare diseases, including Elaprase®, Replagal® and Vpriv®. Prior to his tenure at Shire, Dr. Dai served as the Head of Process Development at ImmunoGen, Inc., an antibody drug conjugates (ADC) drug development company, where he led the process development of multiple ADC drugs, including Kadcyla® (T-DM1) from its research and clinical stages to the commercial stage, which is the first ADC in the world to hit blockbuster status with annual sales surpassed $1B.
       Dr. Dai received a B.S. in Biochemistry and an M.S. in biochemistry and molecular biology from Peking University and a Ph.D. in biochemistry and molecular biology from Chinese Academy of Sciences. He completed his postdoctoral research at Harvard University.

Yong Dai, Ph.D.

Philip Reilly, Ph.D.

Philip Reilly, Ph.D.

Philip Reilly, Ph.D.

       Philip is a venture partner at Third Rock Ventures and has served as chief medical officer of Goldfinch Bio, co-founder of Fulcrum Therapeutics, co-founder and chief medical officer of Voyager Therapeutics, chief medical officer of Bluebird Bio, co-founder of Edimer, among other startup roles. He served as chairman and CEO of Interleukin Genetics. He earned his medical degree at the Yale School of Medicine.
       Philip has authored or co-authored more than 100 articles in scholarly journals and has published seven books including most recently Orphan: The Quest to Save Children with Rare Genetic Disorders. Phil currently serves on the Advisory Board to the Boston University School of Public Health, and has served as a trustee emeritus of Cornell University, an Overseer of Weill Cornell Medical College.

Philip Reilly, Ph.D.

Robert Kotin, Ph.D.

Robert Kotin, Ph.D.

Robert Kotin, Ph.D.

       Dr. Robert Kotin has been a leader in adeno-associated virus (AAV) research for over 30 years, beginning as a post-doctoral fellow at Cornell University Medical Center (now Weill), where he discovered a common integration site for AAV DNA in human chromosome 19, which he designated AAVS1 locus. He spent most of his career in the Intramural Research Program at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) as a tenure track investigator then as a tenured senior investigator and Head of the Laboratory of Molecular Biology and Gene Therapy.
       While at the NIH, Dr. Kotin’s laboratory cloned and sequenced AAV4 and AAV5 and demonstrated that these serotypes may be “vectorized” ushering in the pursuit of novel capsids with different biological properties. Dr. Kotin invented and developed a scalable recombinant adeno-associated virus (rAAV) production process in Sf9 cells which has been licensed by several companies, including uniQure, Voyager Therapeutics, and Biomarin, for clinical development. His laboratory’s research at the NIH resulted in the discovery of an AAV replication product that has been described as closed-ended linear duplex DNA that may serve as an alternative to plasmid DNA for non-viral gene therapy.production process in Sf9 cells which has been licensed by several companies, including uniQure, Voyager Therapeutics, and Biomarin, for clinical development. His laboratory’s research at the NIH resulted in the discovery of an AAV replication product that has been described as closed-ended linear duplex DNA that may serve as an alternative to plasmid DNA for non-viral gene therapy.
       Rob earned his BA in biology from the University of California, Santa Cruz and his PhD from Rutgers University and the University of Medicine and Dentistry of New Jersey (now Robert Wood Johnson Medical School) in microbiology.

Robert Kotin, Ph.D.

Xinyan Li, MD. Ph.D.

Xinyan Li, MD. Ph.D.

Xinyan Li, Ph.D.

       Xinyan Li, Ph.D. is a co-Founder, joined Frontera Therapeutics in October 2020 as the President, leading the Clinical Department responsibility for the Clinical Operations, Medical Affairs, Biometrics, Registration and Marketing. Dr. Li worked 5 years as an internal medicine doctor and 10 years teaching in medical school and conducting scientific research, before starting her journey in drug development as an oversees returnee. Ever since Dr.Li has been engaged in innovative drug R&D management for 20 years, including R&D, preclinical efficacy/safety evaluation, clinical Trials, registration, drug production and quality control (QC and QA), government relations, fund applications, etc.
       As the project leader, Dr. Li successfully led the development of two innovative drugs in China and U.S., and gained valuable management experience in the field of innovative drug R&D. At Carsgen, Dr. Li presided over the pre-clinical, IIT, registered clinical research, and China and US registration of CART cell products.
       As the principal investigator, Dr. Li also led a series of National Significant New Drugs Development Projects during the Eleventh, Twelfth, and Thirteenth Five-year Plan Periods.
       Dr. Li received a B.S. in immunology and Ph. D. in Internal Medicine from the Soochow University, and was a visiting scholar at the Gene and Cell Therapy Center of the University of Montpellier, France.

Xinyan Li, MD. Ph.D.

Yong Dai, Ph.D.

Yong Dai, Ph.D.

       Yong Dai, Ph.D. is a Founder, and the Chief Executive Officer of Frontera Therapeutics since March 2021. Dr. Dai is a proven leader in biologics and gene therapy drug development. He has 20 years of industry experience in successfully building organizations, developing strategy, CMC (chemistry, manufacturing, and controls), and the regulatory submissions spanning all stages of drug development. Before joining Frontera, Dr. Dai most recently served as the Chief Technology Officer at Prevail Therapeutics, a gene therapy company, where he built and led a CMC organization to develop and advance multiple AAV gene therapy drugs including the Parkinson’s disease and other neurodegenerative disorders to the clinical trials. As part of the founding executive team, he fundamentally helped the company to rapidly achieve its IPO on NASDAQ in 2019 and the acquisition by Eli Lilly in 2020. Prior to Prevail, Dr. Dai worked at uniQure, a gene therapy company, where he led the CMC development of all the pipeline programs including a late clinical stage gene therapy drug for Hemophilia B, and a commercial stage drug, Glybera®, the world’s first commercial approved AAV gene therapy drug. Prior to his time at uniQure, he served as the Head of Process Development Commercial Support at Shire Pharmaceuticals, was responsible for the CMC technical supports of all Shire’s commercial biologics drugs for rare diseases, including Elaprase®, Replagal® and Vpriv®. Prior to his tenure at Shire, Dr. Dai served as the Head of Process Development at ImmunoGen, Inc., an antibody drug conjugates (ADC) drug development company, where he led the process development of multiple ADC drugs, including Kadcyla® (T-DM1) from its research and clinical stages to the commercial stage, which is the first ADC in the world to hit blockbuster status with annual sales surpassed $1B.
       Dr. Dai received a B.S. in Biochemistry and an M.S. in biochemistry and molecular biology from Peking University and a Ph.D. in biochemistry and molecular biology from Chinese Academy of Sciences. He completed his postdoctoral research at Harvard University.
Philip Reilly, Ph.D.

Philip Reilly, Ph.D.

       Philip is a venture partner at Third Rock Ventures and has served as chief medical officer of Goldfinch Bio, co-founder of Fulcrum Therapeutics, co-founder and chief medical officer of Voyager Therapeutics, chief medical officer of Bluebird Bio, co-founder of Edimer, among other startup roles. He served as chairman and CEO of Interleukin Genetics. He earned his medical degree at the Yale School of Medicine.
       Philip has authored or co-authored more than 100 articles in scholarly journals and has published seven books including most recently Orphan: The Quest to Save Children with Rare Genetic Disorders. Phil currently serves on the Advisory Board to the Boston University School of Public Health, and has served as a trustee emeritus of Cornell University, an Overseer of Weill Cornell Medical College.
Robert Kotin, Ph.D.

Robert Kotin, Ph.D.

       Dr. Robert Kotin has been a leader in adeno-associated virus (AAV) research for over 30 years, beginning as a post-doctoral fellow at Cornell University Medical Center (now Weill), where he discovered a common integration site for AAV DNA in human chromosome 19, which he designated AAVS1 locus. He spent most of his career in the Intramural Research Program at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) as a tenure track investigator then as a tenured senior investigator and Head of the Laboratory of Molecular Biology and Gene Therapy.
       While at the NIH, Dr. Kotin’s laboratory cloned and sequenced AAV4 and AAV5 and demonstrated that these serotypes may be “vectorized” ushering in the pursuit of novel capsids with different biological properties. Dr. Kotin invented and developed a scalable recombinant adeno-associated virus (rAAV) production process in Sf9 cells which has been licensed by several companies, including uniQure, Voyager Therapeutics, and Biomarin, for clinical development. His laboratory’s research at the NIH resulted in the discovery of an AAV replication product that has been described as closed-ended linear duplex DNA that may serve as an alternative to plasmid DNA for non-viral gene therapy.production process in Sf9 cells which has been licensed by several companies, including uniQure, Voyager Therapeutics, and Biomarin, for clinical development. His laboratory’s research at the NIH resulted in the discovery of an AAV replication product that has been described as closed-ended linear duplex DNA that may serve as an alternative to plasmid DNA for non-viral gene therapy.
       Rob earned his BA in biology from the University of California, Santa Cruz and his PhD from Rutgers University and the University of Medicine and Dentistry of New Jersey (now Robert Wood Johnson Medical School) in microbiology.
Xinyan Li, MD. Ph.D.

Xinyan Li, Ph.D.

       Xinyan Li, Ph.D. is a co-Founder, joined Frontera Therapeutics in October 2020 as the President, leading the Clinical Department responsibility for the Clinical Operations, Medical Affairs, Biometrics, Registration and Marketing. Dr. Li worked 5 years as an internal medicine doctor and 10 years teaching in medical school and conducting scientific research, before starting her journey in drug development as an oversees returnee. Ever since Dr.Li has been engaged in innovative drug R&D management for 20 years, including R&D, preclinical efficacy/safety evaluation, clinical Trials, registration, drug production and quality control (QC and QA), government relations, fund applications, etc.
       As the project leader, Dr. Li successfully led the development of two innovative drugs in China and U.S., and gained valuable management experience in the field of innovative drug R&D. At Carsgen, Dr. Li presided over the pre-clinical, IIT, registered clinical research, and China and US registration of CART cell products.
       As the principal investigator, Dr. Li also led a series of National Significant New Drugs Development Projects during the Eleventh, Twelfth, and Thirteenth Five-year Plan Periods.
       Dr. Li received a B.S. in immunology and Ph. D. in Internal Medicine from the Soochow University, and was a visiting scholar at the Gene and Cell Therapy Center of the University of Montpellier, France.

BOARD OF DIRECTORS

Wei Li, Ph.D., Chairman

Wei Li, Ph.D., Chairman

Founding Partner of Creacion Ventures
Managing Partner, 6 Dimensions Capital
Founding Partner of WuXi Healthcare Ventures
Executive Partner, Fidelity Biosciences
Ph.D. in Biochemistry, Harvard University
MBA, Kellogg School of Management, Northwestern University
Dr. Wei Li has successfully founded a number of domestic and overseas biopharmaceutical companies, including Innovent Biologics (1801.HK), as the founding director of CStone pharmaceuticals (CStone Pharmaceuticals, 261.HK), OcuMension Therapeutics (1477.HK) and Dewpoint Therapeutics.

Wei Li, Ph.D., Chairman

Ching Zhu, Ph.D.

Ching Zhu, Ph.D.

Founding Partner of Creacion Ventures
Managing Partner, 6 Dimensions Capital
Frontline BioVentures Managing Partner
Novitas Capital Partner
Ph.D. in M.D., Oxford Brookes University
EMBA, University of Minnesota, USA
2011 National "Special Expert"
As a scientist, product development designer, serial entrepreneur and venture capitalist, Ching Zhu has extensive technical and management experience in the field of innovative medical device research and development, has more than 300 U.S. patents and 140 global patents, is also a member of the National Institutes of Health's Small Business Innovation Research Jury, has invested in or founded a number of biopharmaceutical medical device companies, including Taigenix, ResQ Inha-Pharma.

Ching Zhu, Ph.D.

David Wang, Ph.D.

David Wang, Ph.D.

Orbimed Global Partner
Managing Partner, WI Harper Group
Ph.D., Developmental Biology, California Institute of Technology
M.D., Department of Medicine, Peking University
David has served at a number of domestic and overseas listed companies including Suzhou MedicalSystem (stock code:603990), Amoy Diagnostics Co., Ltd.(AmoyDx) (stock code:300685), AK Medical Holding Limited (stock code:1789) and Gracell Biotechnologies Inc. (Stock code: GRCL) and other company directors.

David Wang, Ph.D.

Carl Gordon, Ph.D.

Carl Gordon, Ph.D.

Founding Partner of Orbimed
From 2014 to 2019, for five consecutive years, was named the "World's Top 100 Venture Capitalists" by Forbes magazine
Ph.D. in Molecular Biology, Massachusetts Institute of Technology
Bachelor of Science, Harvard; Chartered Financial Analyst
Dr. Carl Gordon is a founding partner of Orbimed and leads Orbimed’s global private equity team. He has served on a number of NASDAQ-listed companies, including Alector Inc. (Stock code: ALEC), Turning Point Therapeutics, Inc. (Stock code: TPTX), Prevail Therapeutics, Inc. (Stock code: PRVL), X4 Pharmaceuticals, Inc. (formerly Arsanis, Inc.) (Stock Code: XFOR), Acceleron Pharma Inc., (Stock Code: XLRN), ARMO BioSciences, Inc. (Stock code: ARMO), Intellia Therapeutics, Inc. (Stock code: NTLA), Selecta Biosciences, Inc. (Stock code: SELB), SpringWorks Therapeutics, Inc. (Stock code: SWTX) and Passage Bio Inc. (Stock code: PASG).

Carl Gordon, Ph.D.

Yong Dai, Ph.D.

Yong Dai, Ph.D.

Founder, CEO, Frontera
Former CTO, Prevail Therapeutics
Head of CMC, uniQure
Head of Process Development Commercial Supports, Shire Pharmaceuticals
Head of ADC Process Development, ImmunoGen, Inc
Research Fellow, Molecular and Cell Biology, Harvard University
Ph.D. , Biochemistry and Molecular Biology, Chinese Academy of Sciences
Bachelor of Science, Peking University
Dr. Dai is a proven leader in biologics and gene therapy drug development. He has 20 years of industry experience in successfully building organizations and functions, developing strategy, CMC (chemistry, manufacturing, and controls), and the regulatory submissions spanning all stages of drug development.

Yong Dai, Ph.D.

Xinyan Li, MD. Ph.D.

Xinyan Li, MD. Ph.D.

Co-Founder, President, Chief Medical Officer
Former Senior Vice President, CARsgen Therapeutics Co., Ltd
Former Chief Medical Officer of KPC Pharmaceuticals, Inc.
Former Executive Deputy General Manager and CMO of Zensun (Shanghai) Sci & Tech Co., Ltd.
Visiting Scholar, Gene and Cell Therapy Center, University of Montpellier, France
Associate Professor of Immunology, Suzhou University School of Medicine
Dr. Li has been managing the research and development of innovative drugs for 20 years and has built outstanding leadership experience in the field of new drug R&D.

Xinyan Li, MD. Ph.D.

Yanling Cao

Yanling Cao

Founding member and partner of Boyu Capital
Member of the Board of Directors of several leading pharmaceutical, diagnostic and medical health services companies in China
Responsible for strategic in the investment expertise and financial transactions in General Atlantic and Goldman Sachs
Bachelor of Economics and Mathematics, Middlebury College

Yanling Cao

Jiang Han

Jiang Han

Managing Director, Sequoia Capital China
Former partner of TF Capital and Proxima Ventures
Major in Biological Sciences, China University of Science and Technology

Jiang Han

Wei Li, Ph.D., Chairman

Wei Li, Ph.D., Chairman

Founding Partner of Creacion Ventures
Managing Partner, 6 Dimensions Capital
Founding Partner of WuXi Healthcare Ventures
Executive Partner, Fidelity Biosciences
Ph.D. in Biochemistry, Harvard University
MBA, Kellogg School of Management, Northwestern University
Dr. Wei Li has successfully founded a number of domestic and overseas biopharmaceutical companies, including Innovent Biologics (1801.HK), as the founding director of CStone pharmaceuticals (CStone Pharmaceuticals, 261.HK), OcuMension Therapeutics (1477.HK) and Dewpoint Therapeutics.
Ching Zhu, Ph.D.

Ching Zhu, Ph.D.

Founding Partner of Creacion Ventures
Managing Partner, 6 Dimensions Capital
Frontline BioVentures Managing Partner
Novitas Capital Partner
Ph.D. in M.D., Oxford Brookes University
EMBA, University of Minnesota, USA
2011 National "Special Expert"
As a scientist, product development designer, serial entrepreneur and venture capitalist, Ching Zhu has extensive technical and management experience in the field of innovative medical device research and development, has more than 300 U.S. patents and 140 global patents, is also a member of the National Institutes of Health's Small Business Innovation Research Jury, has invested in or founded a number of biopharmaceutical medical device companies, including Taigenix, ResQ Inha-Pharma.
David Wang, Ph.D.

David Wang, Ph.D.

Orbimed Global Partner
Managing Partner, WI Harper Group
Ph.D., Developmental Biology, California Institute of Technology
M.D., Department of Medicine, Peking University
David has served at a number of domestic and overseas listed companies including Suzhou MedicalSystem (stock code:603990), Amoy Diagnostics Co., Ltd.(AmoyDx) (stock code:300685), AK Medical Holding Limited (stock code:1789) and Gracell Biotechnologies Inc. (Stock code: GRCL) and other company directors.
Carl Gordon, Ph.D.

Carl Gordon, Ph.D.

Founding Partner of Orbimed
From 2014 to 2019, for five consecutive years, was named the "World's Top 100 Venture Capitalists" by Forbes magazine
Ph.D. in Molecular Biology, Massachusetts Institute of Technology
Bachelor of Science, Harvard; Chartered Financial Analyst
Dr. Carl Gordon is a founding partner of Orbimed and leads Orbimed’s global private equity team. He has served on a number of NASDAQ-listed companies, including Alector Inc. (Stock code: ALEC), Turning Point Therapeutics, Inc. (Stock code: TPTX), Prevail Therapeutics, Inc. (Stock code: PRVL), X4 Pharmaceuticals, Inc. (formerly Arsanis, Inc.) (Stock Code: XFOR), Acceleron Pharma Inc., (Stock Code: XLRN), ARMO BioSciences, Inc. (Stock code: ARMO), Intellia Therapeutics, Inc. (Stock code: NTLA), Selecta Biosciences, Inc. (Stock code: SELB), SpringWorks Therapeutics, Inc. (Stock code: SWTX) and Passage Bio Inc. (Stock code: PASG).
Yong Dai, Ph.D.

Yong Dai, Ph.D.

Founder, CEO, Frontera
Former CTO, Prevail Therapeutics
Head of CMC, uniQure
Head of Process Development Commercial Supports, Shire Pharmaceuticals
Head of ADC Process Development, ImmunoGen, Inc
Research Fellow, Molecular and Cell Biology, Harvard University
Ph.D. , Biochemistry and Molecular Biology, Chinese Academy of Sciences
Bachelor of Science, Peking University
Dr. Dai is a proven leader in biologics and gene therapy drug development. He has 20 years of industry experience in successfully building organizations and functions, developing strategy, CMC (chemistry, manufacturing, and controls), and the regulatory submissions spanning all stages of drug development.
Xinyan Li, MD. Ph.D.

Xinyan Li, MD. Ph.D.

Co-Founder, President, Chief Medical Officer
Former Senior Vice President, CARsgen Therapeutics Co., Ltd
Former Chief Medical Officer of KPC Pharmaceuticals, Inc.
Former Executive Deputy General Manager and CMO of Zensun (Shanghai) Sci & Tech Co., Ltd.
Visiting Scholar, Gene and Cell Therapy Center, University of Montpellier, France
Associate Professor of Immunology, Suzhou University School of Medicine
Dr. Li has been managing the research and development of innovative drugs for 20 years and has built outstanding leadership experience in the field of new drug R&D.
Yanling Cao

Yanling Cao

Founding member and partner of Boyu Capital
Member of the Board of Directors of several leading pharmaceutical, diagnostic and medical health services companies in China
Responsible for strategic in the investment expertise and financial transactions in General Atlantic and Goldman Sachs
Bachelor of Economics and Mathematics, Middlebury College
Jiang Han

Jiang Han

Managing Director, Sequoia Capital China
Former partner of TF Capital and Proxima Ventures
Major in Biological Sciences, China University of Science and Technology

LEADERSHIP TEAM

The senior management team of Frontera all have many years of experience serving leading roles in global pharmaceutical companies as well as innovative biotech. Their expertise spans from early research and development of gene therapy products and biologics, CMC, clinical trials, business development, registration, to commercialization.

Yong Dai, Ph.D.

Yong Dai, Ph.D.

Founder, Chief Executive Officer

       Yong Dai, Ph.D. is a Founder, and the Chief Executive Officer of Frontera Therapeutics since March 2021. Dr. Dai is a proven leader in biologics and gene therapy drug development. He has 20 years of industry experience in successfully building organizations, developing strategy, CMC (chemistry, manufacturing, and controls), and the regulatory submissions spanning all stages of drug development. Before joining Frontera, Dr. Dai most recently served as the Chief Technology Officer at Prevail Therapeutics, a gene therapy company, where he built and led a CMC organization to develop and advance multiple AAV gene therapy drugs including the Parkinson’s disease and other neurodegenerative disorders to the clinical trials. As part of the founding executive team, he fundamentally helped the company to rapidly achieve its IPO on NASDAQ in 2019 and the acquisition by Eli Lilly in 2020. Prior to Prevail, Dr. Dai worked at uniQure, a gene therapy company, where he served as Head of CMC for the development of all the pipeline programs including a late clinical stage Hemophilia B gene therapy drug , and a commercial stage drug, Glybera®, the world’s first commercial approved AAV gene therapy drug. Prior to his time at uniQure, he served as the Head of Process Development Commercial Support at Shire Pharmaceuticals, was responsible for the CMC technical supports of all Shire’s commercial biologics drugs for rare diseases, including Elaprase®, Replagal® and Vpriv®. Prior to his tenure at Shire, Dr. Dai served as the Head of Process Development at ImmunoGen, Inc., an antibody drug conjugates (ADC) drug development company, where he led the process development of multiple ADC drugs, including Kadcyla® (T-DM1) from its research and clinical stages to the commercial stage, which is the first ADC in the world to hit blockbuster status with annual sales surpassed $1B.
       Dr. Dai received a B.S. in Biochemistry and an M.S. in biochemistry and molecular biology from Peking University and a Ph.D. in biochemistry and molecular biology from Chinese Academy of Sciences. He completed his postdoctoral research at Harvard University.

Yong Dai, Ph.D.

Xinyan Li, MD. Ph.D.

Xinyan Li, MD. Ph.D.

Co-Founder, President, Chief Medical Officer

       Xinyan Li, Ph.D., joined Frontera Therapeutics in October 2020 as the President, leading the Clinical Department responsibility for the Clinical Operations, Medical Affairs, Biometrics, Registration and Marketing. Dr. Li worked 5 years as an internal medicine doctor and 10 years teaching in medical school and conducting scientific research, before starting her journey in drug development as an oversees returnee. Ever since Dr.Li has been engaged in innovative drug R&D management for 20 years, including R&D, preclinical efficacy/safety evaluation, clinical Trials, registration, drug production and quality control (QC and QA), government relations, fund applications, etc.
       As the project leader, Dr. Li successfully led the development of two innovative drugs in China and U.S., and gained valuable management experience in the field of innovative drug R&D. At Carsgen, Dr. Li presided over the pre-clinical, IIT, registered clinical research, and China and US registration of CART cell products.
       As the principal investigator, Dr. Li also led a series of National Significant New Drugs Development Projects during the Eleventh, Twelfth, and Thirteenth Five-year Plan Periods.
       Dr. Li received a B.S. in immunology and Ph. D. in Internal Medicine from the Soochow University, and was a visiting scholar at the Gene and Cell Therapy Center of the University of Montpellier, France.

Xinyan Li, MD. Ph.D.

Stephen Lau

Stephen Lau

Chief Business Officer

       Stephen joined Fontera Therapeutics in March 2022 as Chief Business Officer.  He has over 20 years of biotech operating and deal-making experiences, having been in various C-level roles and completed over 60 business development, M&A, and financing transactions.  
       Most recently, he was Chief Operating Officer at Innovent Biologics (HKEX: 1801), where he led the execution of a portfolio of immune-oncology Phase 1/2 clinical trials in the US, as well as being head of global business development strategy.  Prior to Innovent, from 2013-2019, he was Founder & CEO of BioClin (aka Rainier) Therapeutics, Inc., an orphan disease and oncology private biotech company.  He in-licensed a drug from Genentech, raised $79M in venture financing from top-tier US and European healthcare investors, built a team who filed a pre-IND in Achondroplasia, and ultimately completed a number of Phase 2 clinical studies in metastatic bladder cancer in over 100 clinical sites worldwide.  Prior to BioClin, from 2008-2012, he was Vice President of Corporate & Business Development at Anthera Pharmaceuticals Inc. (NASDAQ: ANTH).  Prior to Anthera, from 2003-2008, he was at Amgen Inc. (NASDAQ: AMGN), where he was responsible for managing and negotiating-in and out-licensing transactions.  Prior to Amgen, from 2001-2003, he was a key member of the healthcare investment banking group at Canaccord Genuity (aka Adams, Harkness & Hill), where he helped biopharmaceutical and medical device companies raise over $2 billion in public and private financings, and executed M&A transactions.
        Earlier in his career, he was a management consultant for Strategic Decisions Group, Deloitte Consulting and Hay Management Consulting, where he advised Fortune 500 healthcare and technology companies on strategic and portfolio management issues.  He also managed late-stage HIV clinical trials at University of California Davis Medical Center and conducted immunology research. 
       Stephen received his B.A. in Microbiology and M.S. in Immunology from the University of California Davis, and a Master's in Health Care Management from Harvard University.

Stephen Lau

Dean Falb, Ph.D.

Dean Falb, Ph.D.

Chief Scientific Officer

       Dean joined Frontera Therapeutics in May 2022 as the Chief Scientific Officer.  He has over 25 years of experience in building and leading research and development teams in early-stage platform biotechnology companies.
       Most recently, he was the Chief Scientific Officer at PlateletBio, an allogeneic engineered iPSC cell therapy company focused on rare autoimmune diseases.  Prior to PlateletBio, he was the CSO at LogicBio (NASDAQ: LOGC), an AAV gene therapy/gene editing company focused on rare genetic diseases.  In 2012, Dean was an Entrepreneur-In-Residence at Atlas Ventures, where he founded Synlogic Therapeutics (NASDAQ: SYBX) and served as its Chief Technology Officer until 2018.  During his tenure there, he oversaw the company’s filing of INDs in oncology and several rare disease indications including phenylketonuria and urea cycle disorders.
       Dean began his career as a scientist at Millennium Pharmaceuticals (NASDAQ: TAK) at the company’s inception in 1993, and founded and led its program in the genomics and genetics of cardiovascular diseases until 1998.  There he also led the company’s partnership with Eli Lilly. Following Millennium, Dean served as SVP of Research and Development at Praecis Pharmaceuticals (GSK), focused on oncology, and was VP of Research at Stryker’s Regenerative Medicine Division (NYSE: SYK) where he was responsible for leading its programs in osteoarthritis and tissue fibrosis.
       Dean received his B.S. in chemistry from Purdue University, and a Ph.D. in Biochemistry and Molecular Biology from Harvard University.

Dean Falb, Ph.D.

Shawn Harriman, Ph.D.

Shawn Harriman, Ph.D.

Chief Development Officer

       Shawn Harriman, Ph.D., joined Frontera Therapeutics in April 2021 as the Chief Development Officer, Head of Research and Development,a role to which he brings over 25 years of experience as a scientist and organization leader in the pharmaceutical and biotechnology industries. During his tenure in industry, he contributed to shaping a portfolio of effective agents to treat diseases across multiple therapeutic areas, using a mixture of internal resource, industrial and academic collaborations, and strategic outsourcing. He has extensive experience successfully translating multiple medicinal candidates into clinical development across a diverse set of modalities (small molecules, peptides, siRNA, antibody-drug conjugates, RNA-based therapies, and gene therapy). Before joining Frontera, Dr, Harriman was Vice President of Translational Sciences at Sarepta Therapeutics. In this position, he was responsible for the leadership, operational, and strategic management of the Translational Sciences function within the R&D organization. In this role, he was responsible for biological validation of numerous neuromuscular disease targets, quantitative biology/pharmacology, DMPK, M&S, in vitro and in vivo model development, quantitative assay development and implementation, preclinical safety, and clinical biomarkers) to advance both RNA oligonucleotide and AAV-based gene therapy candidates from discovery to the clinic and post-marketing activities. At Sarepta, Dr. Harriman was a key contributor in the company obtaining accelerated FDA approval of two medicinal products, Vyondys and Amondys for the treatment of Duchenne Muscular Dystrophy (DMD). Additionally, he was responsible for progressing multiple peptide-conjugated phosphorodiamidate morpholino oligomers and AAV-based gene therapy preclinical candidates into advanced clinical evaluation in patients. Prior to Sarepta, Dr. Harriman was the Vice President of Preclinical Development and Clinical Pharmacology at Summit Therapeutics where he led Summit’s global discovery and preclinical organization towards the discovery and development of novel therapies for the treatment of Duchenne muscular dystrophy (DMD). Before his time at Summit, he held positions of increasing leadership responsibility during his 17+-year tenure in big pharma (Pfizer and Novartis) where he was responsible for establishing and leading the Metabolism and Pharmacokinetics Department. In this role, Dr. Harriman made significant contributions to the advancement of new medical entities spanning multiple therapeutic areas including, Oncology, Metabolic Diseases, Cardiovascular, Infectious Disease and Ophthalmology which culminated to over 30 INDs.
       Dr. Harriman received a B.S. in Zoology and an M.S. in Pharmaceutical Sciences from the University of Rhode Island. Dr. Harriman received his Ph.D. in Medicinal Chemistry from the University of Kansas and completed his postdoctoral research at Massachusetts Institute of Technology.

Shawn Harriman, Ph.D.

Robert Lu, Ph.D.

Robert Lu, Ph.D.

VP of Technical Operations

       Robert Lu, Ph.D., joined Frontera Therapeutics in February 2020 as the VP of Technical Operations. Dr. Lu has over 17 years of biotechnology industry experience in corporate strategy, CMC, and regulatory submissions at different stages of drug development. Before joining Frontera, he was the VP of Process Development and Analytical Development at Solid Biosciences. In this role, he has led the AAV process development and manufacturing from a research concept to IND submission within 18 months (SGT-001 for the treatment of Duchenne muscular dystrophy, DMD). He has also led the second-generation process development to improve the AAV quality to reduce the clinical safety concerns. Prior to Solid Biosciences, Dr. Lu was the manager of MSAT at Sanofi Genzyme, where he has successfully led the process improvement of Cerezyme’s commercial process which resulted in 25% manufacturing yield increase. Before his time at Sanofi Genzyme, he held positions of increasing leadership responsibility at Shire and Percivia, where he made contributions to the advancement of new drug candidates from research to development in multiple therapeutic areas including Oncology, Metabolic Diseases, and Enzyme Replacement Therapies.
       Dr. Lu received his B.S. in Biochemistry from Peking University in China, and Ph.D. in Chemistry from Brown University, and completed his postdoctoral research at Harvard Medical School.

Robert Lu, Ph.D.

Allison Jia

Allison Jia

VP of Finance

       Allison Jia joined Frontera in Apr 2021 as the Finance VP of the company. She has 20 years of extensive working experience in financial operation and management. Prior to Frontera, Allison worked as the finance VP of Panexwd Group where she takes charge of the overall global finance function of the company. Starting from auditing in PWC, Allison gained solid skills and experience in corporate finance in her later roles of accounting manager in Taiping Life, Finance Head in Zensun and Agility Logistics GCA DIL respectively. Her capacity includes fulfilling financial reporting commitment for listed companies, setting up financial control policies and process and budgeting system, implementing and upgrading ERP system, leading M&A project and getting finance from banks and investors.
       Allison received her BS degree with double majors of English and International Accounting as well as MA degree of Linguistics from Shanghai Jiaotong University. She is a fellow member of ACCA.

Allison Jia

Baochuan Huang

Baochuan Huang

SVP of Manufacturing

       Baochuan Huang joined Frontera in May 2021 as Senior Vice President and Head of Frontera’s Manufacturing Site at Suzhou, China. Prior to joining Frontera, Baochuan had worked in the biotechnology and pharmaceutical field for 20 years, most recently as Vice President of CMC at Abpro Corp.
       Baochuan received most of his professional trainings from international biopharmaceutical companies like Amgen, Shire and Baxter. He worked there for over 14 years and developed expertise in different areas of CMC, from cell line, process development, scale up and tech transfer, to GMP manufacturing, process validation and BLA applications. During his eight years at Amgen, he provided technical support to productions of hemophilia drug Aranesp, and led tech transfer of more than a dozen upstream processes from research to GMP manufacturing, including the block buster bone drug Prolia and diabetes drug Repatha.
       From 2015 to 2021, Baochuan took CMC/Technical leadership roles at innovative smaller biotech TESARO, KINIKSA and ABPRO. He successful led cross-functional team to IND approvals of multiple protein drugs in US/EU in the field of oncology, inflammation and autoimmune disease. He is patent co-owner for multiple innovative molecules including commercial PD-1 antibody Dostarlimab, and Cobolimab which is in phase 3 clinical development.
       Baochuan obtained BS/MS degree in Fermentation Engineering from Tianjin University of Science and Technology, China and Master’s degree in Chemical Engineering from Montana State University at Bozeman.

Baochuan Huang

Previous page
1
Yong Dai, Ph.D.

Yong Dai, Ph.D.

Founder, Chief Executive Officer

       Yong Dai, Ph.D. is a Founder, and the Chief Executive Officer of Frontera Therapeutics since March 2021. Dr. Dai is a proven leader in biologics and gene therapy drug development. He has 20 years of industry experience in successfully building organizations, developing strategy, CMC (chemistry, manufacturing, and controls), and the regulatory submissions spanning all stages of drug development. Before joining Frontera, Dr. Dai most recently served as the Chief Technology Officer at Prevail Therapeutics, a gene therapy company, where he built and led a CMC organization to develop and advance multiple AAV gene therapy drugs including the Parkinson’s disease and other neurodegenerative disorders to the clinical trials. As part of the founding executive team, he fundamentally helped the company to rapidly achieve its IPO on NASDAQ in 2019 and the acquisition by Eli Lilly in 2020. Prior to Prevail, Dr. Dai worked at uniQure, a gene therapy company, where he served as Head of CMC for the development of all the pipeline programs including a late clinical stage Hemophilia B gene therapy drug , and a commercial stage drug, Glybera®, the world’s first commercial approved AAV gene therapy drug. Prior to his time at uniQure, he served as the Head of Process Development Commercial Support at Shire Pharmaceuticals, was responsible for the CMC technical supports of all Shire’s commercial biologics drugs for rare diseases, including Elaprase®, Replagal® and Vpriv®. Prior to his tenure at Shire, Dr. Dai served as the Head of Process Development at ImmunoGen, Inc., an antibody drug conjugates (ADC) drug development company, where he led the process development of multiple ADC drugs, including Kadcyla® (T-DM1) from its research and clinical stages to the commercial stage, which is the first ADC in the world to hit blockbuster status with annual sales surpassed $1B.
       Dr. Dai received a B.S. in Biochemistry and an M.S. in biochemistry and molecular biology from Peking University and a Ph.D. in biochemistry and molecular biology from Chinese Academy of Sciences. He completed his postdoctoral research at Harvard University.
Xinyan Li, MD. Ph.D.

Xinyan Li, MD. Ph.D.

Co-Founder, President, Chief Medical Officer

       Xinyan Li, Ph.D., joined Frontera Therapeutics in October 2020 as the President, leading the Clinical Department responsibility for the Clinical Operations, Medical Affairs, Biometrics, Registration and Marketing. Dr. Li worked 5 years as an internal medicine doctor and 10 years teaching in medical school and conducting scientific research, before starting her journey in drug development as an oversees returnee. Ever since Dr.Li has been engaged in innovative drug R&D management for 20 years, including R&D, preclinical efficacy/safety evaluation, clinical Trials, registration, drug production and quality control (QC and QA), government relations, fund applications, etc.
       As the project leader, Dr. Li successfully led the development of two innovative drugs in China and U.S., and gained valuable management experience in the field of innovative drug R&D. At Carsgen, Dr. Li presided over the pre-clinical, IIT, registered clinical research, and China and US registration of CART cell products.
       As the principal investigator, Dr. Li also led a series of National Significant New Drugs Development Projects during the Eleventh, Twelfth, and Thirteenth Five-year Plan Periods.
       Dr. Li received a B.S. in immunology and Ph. D. in Internal Medicine from the Soochow University, and was a visiting scholar at the Gene and Cell Therapy Center of the University of Montpellier, France.
Stephen Lau

Stephen Lau

Chief Business Officer

       Stephen joined Fontera Therapeutics in March 2022 as Chief Business Officer.  He has over 20 years of biotech operating and deal-making experiences, having been in various C-level roles and completed over 60 business development, M&A, and financing transactions.  
       Most recently, he was Chief Operating Officer at Innovent Biologics (HKEX: 1801), where he led the execution of a portfolio of immune-oncology Phase 1/2 clinical trials in the US, as well as being head of global business development strategy.  Prior to Innovent, from 2013-2019, he was Founder & CEO of BioClin (aka Rainier) Therapeutics, Inc., an orphan disease and oncology private biotech company.  He in-licensed a drug from Genentech, raised $79M in venture financing from top-tier US and European healthcare investors, built a team who filed a pre-IND in Achondroplasia, and ultimately completed a number of Phase 2 clinical studies in metastatic bladder cancer in over 100 clinical sites worldwide.  Prior to BioClin, from 2008-2012, he was Vice President of Corporate & Business Development at Anthera Pharmaceuticals Inc. (NASDAQ: ANTH).  Prior to Anthera, from 2003-2008, he was at Amgen Inc. (NASDAQ: AMGN), where he was responsible for managing and negotiating-in and out-licensing transactions.  Prior to Amgen, from 2001-2003, he was a key member of the healthcare investment banking group at Canaccord Genuity (aka Adams, Harkness & Hill), where he helped biopharmaceutical and medical device companies raise over $2 billion in public and private financings, and executed M&A transactions.
        Earlier in his career, he was a management consultant for Strategic Decisions Group, Deloitte Consulting and Hay Management Consulting, where he advised Fortune 500 healthcare and technology companies on strategic and portfolio management issues.  He also managed late-stage HIV clinical trials at University of California Davis Medical Center and conducted immunology research. 
       Stephen received his B.A. in Microbiology and M.S. in Immunology from the University of California Davis, and a Master's in Health Care Management from Harvard University.
Dean Falb, Ph.D.

Dean Falb, Ph.D.

Chief Scientific Officer

       Dean joined Frontera Therapeutics in May 2022 as the Chief Scientific Officer.  He has over 25 years of experience in building and leading research and development teams in early-stage platform biotechnology companies.
       Most recently, he was the Chief Scientific Officer at PlateletBio, an allogeneic engineered iPSC cell therapy company focused on rare autoimmune diseases.  Prior to PlateletBio, he was the CSO at LogicBio (NASDAQ: LOGC), an AAV gene therapy/gene editing company focused on rare genetic diseases.  In 2012, Dean was an Entrepreneur-In-Residence at Atlas Ventures, where he founded Synlogic Therapeutics (NASDAQ: SYBX) and served as its Chief Technology Officer until 2018.  During his tenure there, he oversaw the company’s filing of INDs in oncology and several rare disease indications including phenylketonuria and urea cycle disorders.
       Dean began his career as a scientist at Millennium Pharmaceuticals (NASDAQ: TAK) at the company’s inception in 1993, and founded and led its program in the genomics and genetics of cardiovascular diseases until 1998.  There he also led the company’s partnership with Eli Lilly. Following Millennium, Dean served as SVP of Research and Development at Praecis Pharmaceuticals (GSK), focused on oncology, and was VP of Research at Stryker’s Regenerative Medicine Division (NYSE: SYK) where he was responsible for leading its programs in osteoarthritis and tissue fibrosis.
       Dean received his B.S. in chemistry from Purdue University, and a Ph.D. in Biochemistry and Molecular Biology from Harvard University.
Shawn Harriman, Ph.D.

Shawn Harriman, Ph.D.

Chief Development Officer

       Shawn Harriman, Ph.D., joined Frontera Therapeutics in April 2021 as the Chief Development Officer, Head of Research and Development,a role to which he brings over 25 years of experience as a scientist and organization leader in the pharmaceutical and biotechnology industries. During his tenure in industry, he contributed to shaping a portfolio of effective agents to treat diseases across multiple therapeutic areas, using a mixture of internal resource, industrial and academic collaborations, and strategic outsourcing. He has extensive experience successfully translating multiple medicinal candidates into clinical development across a diverse set of modalities (small molecules, peptides, siRNA, antibody-drug conjugates, RNA-based therapies, and gene therapy). Before joining Frontera, Dr, Harriman was Vice President of Translational Sciences at Sarepta Therapeutics. In this position, he was responsible for the leadership, operational, and strategic management of the Translational Sciences function within the R&D organization. In this role, he was responsible for biological validation of numerous neuromuscular disease targets, quantitative biology/pharmacology, DMPK, M&S, in vitro and in vivo model development, quantitative assay development and implementation, preclinical safety, and clinical biomarkers) to advance both RNA oligonucleotide and AAV-based gene therapy candidates from discovery to the clinic and post-marketing activities. At Sarepta, Dr. Harriman was a key contributor in the company obtaining accelerated FDA approval of two medicinal products, Vyondys and Amondys for the treatment of Duchenne Muscular Dystrophy (DMD). Additionally, he was responsible for progressing multiple peptide-conjugated phosphorodiamidate morpholino oligomers and AAV-based gene therapy preclinical candidates into advanced clinical evaluation in patients. Prior to Sarepta, Dr. Harriman was the Vice President of Preclinical Development and Clinical Pharmacology at Summit Therapeutics where he led Summit’s global discovery and preclinical organization towards the discovery and development of novel therapies for the treatment of Duchenne muscular dystrophy (DMD). Before his time at Summit, he held positions of increasing leadership responsibility during his 17+-year tenure in big pharma (Pfizer and Novartis) where he was responsible for establishing and leading the Metabolism and Pharmacokinetics Department. In this role, Dr. Harriman made significant contributions to the advancement of new medical entities spanning multiple therapeutic areas including, Oncology, Metabolic Diseases, Cardiovascular, Infectious Disease and Ophthalmology which culminated to over 30 INDs.
       Dr. Harriman received a B.S. in Zoology and an M.S. in Pharmaceutical Sciences from the University of Rhode Island. Dr. Harriman received his Ph.D. in Medicinal Chemistry from the University of Kansas and completed his postdoctoral research at Massachusetts Institute of Technology.
Robert Lu, Ph.D.

Robert Lu, Ph.D.

VP of Technical Operations

       Robert Lu, Ph.D., joined Frontera Therapeutics in February 2020 as the VP of Technical Operations. Dr. Lu has over 17 years of biotechnology industry experience in corporate strategy, CMC, and regulatory submissions at different stages of drug development. Before joining Frontera, he was the VP of Process Development and Analytical Development at Solid Biosciences. In this role, he has led the AAV process development and manufacturing from a research concept to IND submission within 18 months (SGT-001 for the treatment of Duchenne muscular dystrophy, DMD). He has also led the second-generation process development to improve the AAV quality to reduce the clinical safety concerns. Prior to Solid Biosciences, Dr. Lu was the manager of MSAT at Sanofi Genzyme, where he has successfully led the process improvement of Cerezyme’s commercial process which resulted in 25% manufacturing yield increase. Before his time at Sanofi Genzyme, he held positions of increasing leadership responsibility at Shire and Percivia, where he made contributions to the advancement of new drug candidates from research to development in multiple therapeutic areas including Oncology, Metabolic Diseases, and Enzyme Replacement Therapies.
       Dr. Lu received his B.S. in Biochemistry from Peking University in China, and Ph.D. in Chemistry from Brown University, and completed his postdoctoral research at Harvard Medical School.
Allison Jia

Allison Jia

VP of Finance

       Allison Jia joined Frontera in Apr 2021 as the Finance VP of the company. She has 20 years of extensive working experience in financial operation and management. Prior to Frontera, Allison worked as the finance VP of Panexwd Group where she takes charge of the overall global finance function of the company. Starting from auditing in PWC, Allison gained solid skills and experience in corporate finance in her later roles of accounting manager in Taiping Life, Finance Head in Zensun and Agility Logistics GCA DIL respectively. Her capacity includes fulfilling financial reporting commitment for listed companies, setting up financial control policies and process and budgeting system, implementing and upgrading ERP system, leading M&A project and getting finance from banks and investors.
       Allison received her BS degree with double majors of English and International Accounting as well as MA degree of Linguistics from Shanghai Jiaotong University. She is a fellow member of ACCA.
Baochuan Huang

Baochuan Huang

SVP of Manufacturing

       Baochuan Huang joined Frontera in May 2021 as Senior Vice President and Head of Frontera’s Manufacturing Site at Suzhou, China. Prior to joining Frontera, Baochuan had worked in the biotechnology and pharmaceutical field for 20 years, most recently as Vice President of CMC at Abpro Corp.
       Baochuan received most of his professional trainings from international biopharmaceutical companies like Amgen, Shire and Baxter. He worked there for over 14 years and developed expertise in different areas of CMC, from cell line, process development, scale up and tech transfer, to GMP manufacturing, process validation and BLA applications. During his eight years at Amgen, he provided technical support to productions of hemophilia drug Aranesp, and led tech transfer of more than a dozen upstream processes from research to GMP manufacturing, including the block buster bone drug Prolia and diabetes drug Repatha.
       From 2015 to 2021, Baochuan took CMC/Technical leadership roles at innovative smaller biotech TESARO, KINIKSA and ABPRO. He successful led cross-functional team to IND approvals of multiple protein drugs in US/EU in the field of oncology, inflammation and autoimmune disease. He is patent co-owner for multiple innovative molecules including commercial PD-1 antibody Dostarlimab, and Cobolimab which is in phase 3 clinical development.
       Baochuan obtained BS/MS degree in Fermentation Engineering from Tianjin University of Science and Technology, China and Master’s degree in Chemical Engineering from Montana State University at Bozeman.

Science Advisory Board

Philip Reilly, Ph.D. (Chair)

Philip Reilly, Ph.D. (Chair)

       Philp is a venture partner at Third Rock Ventures and has served as chief medical officer of Goldfinch Bio, co-founder of Fulcrum Therapeutics, co-founder and chief medical officer of Voyager Therapeutics, chief medical officer of Bluebird Bio, co-founder of Edimer, among other startup roles. He served as chairman and CEO of Interleukin Genetics. He earned his medical degree at the Yale School of Medicine.
       Philp has authored or co-authored more than 100 articles in scholarly journals and has published seven books including most recently Orphan: The Quest to Save Children with Rare Genetic Disorders. Phil currently serves on the Advisory Board to the Boston University School of Public Health, and has served as a trustee emeritus of Cornell University, an Overseer of Weill Cornell Medical College.

Philip Reilly, Ph.D. (Chair)

Robert Kotin, Ph.D.

Robert Kotin, Ph.D.

       Dr. Robert Kotin has been a leader in adeno-associated virus (AAV) research for over 30 years, beginning as a post-doctoral fellow at Cornell University Medical Center (now Weill), where he discovered a common integration site for AAV DNA in human chromosome 19, which he designated AAVS1 locus. He spent most of his career in the Intramural Research Program at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) as a tenure track investigator then as a tenured senior investigator and Head of the Laboratory of Molecular Biology and Gene Therapy.
       While at the NIH, Dr. Kotin’s laboratory cloned and sequenced AAV4 and AAV5 and demonstrated that these serotypes may be “vectorized” ushering in the pursuit of novel capsids with different biological properties. Dr. Kotin invented and developed a scalable recombinant adeno-associated virus (rAAV) production process in Sf9 cells which has been licensed by several companies, including uniQure, Voyager Therapeutics, and BioMarin, for clinical development. His laboratory’s research at the NIH resulted in the discovery of an AAV replication product that has been described as closed-ended linear duplex DNA that may serve as an alternative to plasmid DNA for non-viral gene therapy.
       Rob earned his BA in biology from the University of California, Santa Cruz and his PhD from Rutgers University and the University of Medicine and Dentistry of New Jersey (now Robert Wood Johnson Medical School) in microbiology

Robert Kotin, Ph.D.

Fraser Wright, Ph.D.

Fraser Wright, Ph.D.

       Dr. Wright is a Professor of Pediatrics in the Center for Definitive and Curative Medicine at Stanford University. He was also the co-founder and Chief Technology Officer of Spark Therapeutics, where he helped oversee the product development and manufacturing of LUXTURNA® and other pipeline programs. Prior to co-founding Spark Therapeutics, Dr. Wright was the founding Scientific Director of the Clinical Vector Core Laboratory at the Children’s Hospital of Philadelphia.
       Dr. Wright received his PhD in biochemistry and molecular immunology and his undergraduate degree in biochemistry and physiology from the University of Toronto.

Fraser Wright, Ph.D.

George Church, Ph.D.

George Church, Ph.D.

       George leads Synthetic Biology at the Wyss Institute, where he oversees the directed evolution of molecules, polymers, and whole genomes to create new tools with applications in regenerative medicine and bio-production of chemicals. Among his recent work at the Wyss is development of a technology for synthesizing whole genes, and engineering whole genomes, far faster, more accurate, and less costly than current methods. George is widely recognized for his innovative contributions to genomic science and his many pioneering contributions to chemistry and biomedicine. In 1984, he developed the first direct genomic sequencing method, which resulted in the first genome sequence (the human pathogen, H. pylori). He helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. George invented the broadly applied concepts of molecular multiplexing and tags, homologous recombination methods, and array DNA synthesizers. His many innovations have been the basis for a number of companies including Editas (Gene therapy); Gen9bio (Synthetic DNA); and Veritas Genetics (full human genome sequencing).
       George is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He is Director of the U.S. Department of Energy Technology Center and Director of the National Institutes of Health Center of Excellence in Genomic Science. He has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute and election to the National Academy of Sciences and Engineering.

George Church, Ph.D.

Jean Bennett, Ph.D.

Jean Bennett, Ph.D.

       Jean Bennett, Ph.D., M.D., is the F.M. Kirby Professor of Ophthalmology at the Perelman School of Medicine, University of Pennsylvania. She is also the Director, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania.
       Dr. Bennett graduated with honors with her Bachelor of Science in biology from Yale University in 1976. In 1980, she obtained a Doctorate of Philosophy in Zoology; Cell and Development Biology from the University of California, Berkeley. Bennett continued on to Harvard University to receive her Doctor of Medicine (M.D.) in 1986.
       She has numerous patents for the genetic methods and technologies developed in her laboratory. Jean Bennet’s work has been published over 220 times and she has received many accolades including: the Sanford Lorraine Cross Award, the Antonio Champalimaud Vision Award, the Marian Spencer Fay Award and The Greenberg Prize End Blindness 2020 Award.
       Dr. Jean Bennett is a world leader and pioneering physician-scientist in the field of retinal (eye) gene therapy. She developed the first FDA-approved gene therapy for a genetic disease. Leber’s congenital amaurosis (LCA) is a rare genetic disease causing blindness in children. Individuals who carry mutations in the gene, RPE65, have poor vision at birth and develop LCA, and eventually lose their sight. This treatment, known as Luxturna, restored vision in children and adults with RPE65-related LCA and received historic FDA approval in 2017.

Jean Bennett, Ph.D.

Mark Kay, Ph.D.

Mark Kay, Ph.D.

Mark A. Kay MD, PhD, Dennis Farrey Family Professor, Department of Pediatrics; Professor, Department of Genetics, Stanford University School of Medicine
       Research Description: Dr. Kay’s research for over 25 years is related to gene therapy and non-coding RNA biology and he is an acknowledged leader in this field. He has long been interested in the development of gene transfer vectors for gene therapy as well as manipulating non-coding RNAs for therapeutic purposes. His foundational studies have led to several multi-institutional human trials for gene therapy of conditions like hemophilia. A major interest has been in unraveling the mechanism of viral vector transduction in vivo. His work during the last 15 years has focused on two vector systems, mini-circles and recombinant AAVs (rAAV). Kay’s group has shown that DNA vectors consisting of a circularized eukaryotic expression cassette (lacking plasmid DNA backbone sequences) provide more persistent levels of transgene expression from quiescent tissues compared to the same plasmid vectors. Dr. Kay’s laboratory uncovered insights into how an Adenoviral vector expressing beta-cell transcription factors results in reprogramming of non-beta cells into functional beta- like cells in vivo. Dr. Kay has been an active member of the diabetes and islet biology community, with funded projects with Dr. Markus Grompe previously in the NIH/NIDDK Beta Cell Biology Consortium, and currently is a co-PI on a UO1 project of the Human Islet Resource Network in the Consortium for Targeting and Regeneration (CTAR). Their group is currently investigating mechanisms and methods to develop gene transfer vectors that when delivered by intravenous infusion target native islet cells, or re-program liver cells into functional human beta-cells.

Mark Kay, Ph.D.

Xandra Breakefield, Ph.D.

Xandra Breakefield, Ph.D.

       Xandra Breakefield, Ph.D. is a basic scientist with a strong background in molecular genetics and neuroscience. She focuses her research efforts on: gene therapy for neurologic diseases; and elucidation of the role of extracellular vesicles (EVs) released from cancer cells in tumor progression. She led early studies demonstrating mutant RNA in serum EVs from glioblastoma patients as biomarkers. She did her undergraduate work at Wilson College and her graduate work in Microbial Genetics at Georgetown University. She was a Postdoctoral Fellow with Nobel Prize winner, Dr. Marshall Nirenberg at the NIH. She is currently Professor of Neurology in the Neuroscience Program at Harvard Medical School and Geneticist in the Neurology and Radiology Services at Massachusetts General Hospital.
       Professor Breakefield has received a number of awards for her work, including a McKnight Foundation Neuroscience Development Award, two Javits Neuroscience Investigator Awards, the Society for Neuroscience Mika Salpeter Lifetime Achievement Award, and the Harvard Medical School William Silen Lifetime Achievement Mentoring Award. She is a member of the National Academy of Arts and Sciences and past president of the American Society of Gene and Cell Therapy.

Xandra Breakefield, Ph.D.

Previous page
1
Philip Reilly, Ph.D. (Chair)

Philip Reilly, Ph.D. (Chair)

       Philp is a venture partner at Third Rock Ventures and has served as chief medical officer of Goldfinch Bio, co-founder of Fulcrum Therapeutics, co-founder and chief medical officer of Voyager Therapeutics, chief medical officer of Bluebird Bio, co-founder of Edimer, among other startup roles. He served as chairman and CEO of Interleukin Genetics. He earned his medical degree at the Yale School of Medicine.
       Philp has authored or co-authored more than 100 articles in scholarly journals and has published seven books including most recently Orphan: The Quest to Save Children with Rare Genetic Disorders. Phil currently serves on the Advisory Board to the Boston University School of Public Health, and has served as a trustee emeritus of Cornell University, an Overseer of Weill Cornell Medical College.
Robert Kotin, Ph.D.

Robert Kotin, Ph.D.

       Dr. Robert Kotin has been a leader in adeno-associated virus (AAV) research for over 30 years, beginning as a post-doctoral fellow at Cornell University Medical Center (now Weill), where he discovered a common integration site for AAV DNA in human chromosome 19, which he designated AAVS1 locus. He spent most of his career in the Intramural Research Program at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) as a tenure track investigator then as a tenured senior investigator and Head of the Laboratory of Molecular Biology and Gene Therapy.
       While at the NIH, Dr. Kotin’s laboratory cloned and sequenced AAV4 and AAV5 and demonstrated that these serotypes may be “vectorized” ushering in the pursuit of novel capsids with different biological properties. Dr. Kotin invented and developed a scalable recombinant adeno-associated virus (rAAV) production process in Sf9 cells which has been licensed by several companies, including uniQure, Voyager Therapeutics, and BioMarin, for clinical development. His laboratory’s research at the NIH resulted in the discovery of an AAV replication product that has been described as closed-ended linear duplex DNA that may serve as an alternative to plasmid DNA for non-viral gene therapy.
       Rob earned his BA in biology from the University of California, Santa Cruz and his PhD from Rutgers University and the University of Medicine and Dentistry of New Jersey (now Robert Wood Johnson Medical School) in microbiology
Fraser Wright, Ph.D.

Fraser Wright, Ph.D.

       Dr. Wright is a Professor of Pediatrics in the Center for Definitive and Curative Medicine at Stanford University. He was also the co-founder and Chief Technology Officer of Spark Therapeutics, where he helped oversee the product development and manufacturing of LUXTURNA® and other pipeline programs. Prior to co-founding Spark Therapeutics, Dr. Wright was the founding Scientific Director of the Clinical Vector Core Laboratory at the Children’s Hospital of Philadelphia.
       Dr. Wright received his PhD in biochemistry and molecular immunology and his undergraduate degree in biochemistry and physiology from the University of Toronto.
George Church, Ph.D.

George Church, Ph.D.

       George leads Synthetic Biology at the Wyss Institute, where he oversees the directed evolution of molecules, polymers, and whole genomes to create new tools with applications in regenerative medicine and bio-production of chemicals. Among his recent work at the Wyss is development of a technology for synthesizing whole genes, and engineering whole genomes, far faster, more accurate, and less costly than current methods. George is widely recognized for his innovative contributions to genomic science and his many pioneering contributions to chemistry and biomedicine. In 1984, he developed the first direct genomic sequencing method, which resulted in the first genome sequence (the human pathogen, H. pylori). He helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. George invented the broadly applied concepts of molecular multiplexing and tags, homologous recombination methods, and array DNA synthesizers. His many innovations have been the basis for a number of companies including Editas (Gene therapy); Gen9bio (Synthetic DNA); and Veritas Genetics (full human genome sequencing).
       George is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He is Director of the U.S. Department of Energy Technology Center and Director of the National Institutes of Health Center of Excellence in Genomic Science. He has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute and election to the National Academy of Sciences and Engineering.
Jean Bennett, Ph.D.

Jean Bennett, Ph.D.

       Jean Bennett, Ph.D., M.D., is the F.M. Kirby Professor of Ophthalmology at the Perelman School of Medicine, University of Pennsylvania. She is also the Director, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania.
       Dr. Bennett graduated with honors with her Bachelor of Science in biology from Yale University in 1976. In 1980, she obtained a Doctorate of Philosophy in Zoology; Cell and Development Biology from the University of California, Berkeley. Bennett continued on to Harvard University to receive her Doctor of Medicine (M.D.) in 1986.
       She has numerous patents for the genetic methods and technologies developed in her laboratory. Jean Bennet’s work has been published over 220 times and she has received many accolades including: the Sanford Lorraine Cross Award, the Antonio Champalimaud Vision Award, the Marian Spencer Fay Award and The Greenberg Prize End Blindness 2020 Award.
       Dr. Jean Bennett is a world leader and pioneering physician-scientist in the field of retinal (eye) gene therapy. She developed the first FDA-approved gene therapy for a genetic disease. Leber’s congenital amaurosis (LCA) is a rare genetic disease causing blindness in children. Individuals who carry mutations in the gene, RPE65, have poor vision at birth and develop LCA, and eventually lose their sight. This treatment, known as Luxturna, restored vision in children and adults with RPE65-related LCA and received historic FDA approval in 2017.
Mark Kay, Ph.D.

Mark Kay, Ph.D.

Mark A. Kay MD, PhD, Dennis Farrey Family Professor, Department of Pediatrics; Professor, Department of Genetics, Stanford University School of Medicine
       Research Description: Dr. Kay’s research for over 25 years is related to gene therapy and non-coding RNA biology and he is an acknowledged leader in this field. He has long been interested in the development of gene transfer vectors for gene therapy as well as manipulating non-coding RNAs for therapeutic purposes. His foundational studies have led to several multi-institutional human trials for gene therapy of conditions like hemophilia. A major interest has been in unraveling the mechanism of viral vector transduction in vivo. His work during the last 15 years has focused on two vector systems, mini-circles and recombinant AAVs (rAAV). Kay’s group has shown that DNA vectors consisting of a circularized eukaryotic expression cassette (lacking plasmid DNA backbone sequences) provide more persistent levels of transgene expression from quiescent tissues compared to the same plasmid vectors. Dr. Kay’s laboratory uncovered insights into how an Adenoviral vector expressing beta-cell transcription factors results in reprogramming of non-beta cells into functional beta- like cells in vivo. Dr. Kay has been an active member of the diabetes and islet biology community, with funded projects with Dr. Markus Grompe previously in the NIH/NIDDK Beta Cell Biology Consortium, and currently is a co-PI on a UO1 project of the Human Islet Resource Network in the Consortium for Targeting and Regeneration (CTAR). Their group is currently investigating mechanisms and methods to develop gene transfer vectors that when delivered by intravenous infusion target native islet cells, or re-program liver cells into functional human beta-cells.
Xandra Breakefield, Ph.D.

Xandra Breakefield, Ph.D.

       Xandra Breakefield, Ph.D. is a basic scientist with a strong background in molecular genetics and neuroscience. She focuses her research efforts on: gene therapy for neurologic diseases; and elucidation of the role of extracellular vesicles (EVs) released from cancer cells in tumor progression. She led early studies demonstrating mutant RNA in serum EVs from glioblastoma patients as biomarkers. She did her undergraduate work at Wilson College and her graduate work in Microbial Genetics at Georgetown University. She was a Postdoctoral Fellow with Nobel Prize winner, Dr. Marshall Nirenberg at the NIH. She is currently Professor of Neurology in the Neuroscience Program at Harvard Medical School and Geneticist in the Neurology and Radiology Services at Massachusetts General Hospital.
       Professor Breakefield has received a number of awards for her work, including a McKnight Foundation Neuroscience Development Award, two Javits Neuroscience Investigator Awards, the Society for Neuroscience Mika Salpeter Lifetime Achievement Award, and the Harvard Medical School William Silen Lifetime Achievement Mentoring Award. She is a member of the National Academy of Arts and Sciences and past president of the American Society of Gene and Cell Therapy.

COMPANY HISTORY

Frontera Therapeutics

Company Founded

September 2019

Series B financing completed

April 2021

Frontera Therapeutics
Frontera Therapeutics

Grounding breaking of SuZhou manufacturing plant (China) 

June 2021

SuZhou manufacturing plant launched

December 2021

发展历程

TEAM BUILDING

 Training
Training
Training
 China Team Building
China Team Building
China team building
 New Hire
New Hire
New Hire
 Boston R&D team building
Boston R&D team building
Boston R&D team building
 Ceremony of Starting of construction for the Suzhou manufacturing site
Ceremony of Starting of construction for the Suzhou manufacturing site
Ceremony of Starting of construction for the Suzhou manufacturing site
 Grand opening of new R&D center at Boston
Grand opening of new R&D center at Boston
Grand opening of new R&D center at Boston
Copyright ©2021-2029 Frontera Therapeutics Inc. All Rights Reserved.